Search

Displaying results 9171 - 9180 of 9613 in total
  1. Drug

    AVR-RD-01

    go.drugbank.com/drugs/DB17651
    Investigational

    It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence.

  2. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

  3. Drug

    Asapiprant

    go.drugbank.com/drugs/DB20492
    Investigational

    Asapiprant has a monoisotopic molecular weight of 501.16 Da.

  4. Drug

    Alofanib

    go.drugbank.com/drugs/DB20918
    Investigational

    Alofanib has a monoisotopic molecular weight of 413.07 Da.

  5. Drug

    Serelaxin

    go.drugbank.com/drugs/DB05794
    Investigational

    is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come together).It

  6. Drug

    BGB-DXP593

    go.drugbank.com/drugs/DB16357
    Investigational

    [L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants

  7. Drug

    Devafidugene civaparvovec

    go.drugbank.com/drugs/DB16790
    Investigational

    It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme.

  8. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.

  9. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    [L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

  10. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]